Novo weight loss therapy cuts mortality risk in kidney disease [Seeking Alpha]
Outset Medical, Inc. (OM)
Company Research
Source: Seeking Alpha
the risk of death by 20% in a study for patients with type 2 diabetes and chronic kidney disease. In October, the Danish drugmaker announced an early end to the trial named FLOW after an interim analysis showed early signs of success with semaglutide 1.0 mg. In reaction, shares of dialysis-related companies, including Fresenius ( FMS ), DaVita ( DVA ), Outset Medical ( OM ), and Baxter International ( BAX ), tumbled. In March, the company released more data from the study indicating that semaglutide 1.0 mg given as a weekly injectable with the standard of care achieved the study's primary endpoint, leading to a 24% reduction in the risk of kidney disease-related events. Novo's ( NVO ) rival in the weight loss space, Eli Lilly ( LLY ), whose obesity therapy tirzepatide is also undergoing studies for kidney-related ailments, trended lower after the announcement. The latest readout published in the New England Journal of Medicine and presented at a meeting of the European Renal
Show less
Read more
Impact Snapshot
Event Time:
OM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OM alerts
High impacting Outset Medical, Inc. news events
Weekly update
A roundup of the hottest topics
OM
News
- Outset Medical, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – OMAccesswire
- Levi & Korsinsky Reminds Outset Medical, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – OMAccesswire
- OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud LawsuitPR Newswire
- Outset Medical, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - OMAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc. - OMAccesswire
OM
Earnings
- 8/7/24 - Beat
OM
Sec Filings
- 9/27/24 - Form 8-K
- 9/10/24 - Form SC
- 9/9/24 - Form SC
- OM's page on the SEC website